Spleen in Medical Technology

VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE

... pathway relates to monocyte deployment from the spleen to inflammatory sites, including myocardial ... that monocytes were held in concentration in the spleen and released to injured tissue sites in the body ... "unambiguously the fate of monocytes from the spleen to the heart." "We see the integration of ...

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

... improvements compared with baselines were also observed in platelet and spleen sizes, and nominally significant improvements were observed in liver size ... statistically significant improvements in hemoglobin, platelet count, and spleen volume were also demonstrated. The magnitude of changes in the 45U/kg dose ...

S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis

... more blood cells are made in other organs, such as the liver and spleen which are not as efficient at blood cell production as the bone marrow. CIMF is characterized by an enlarged spleen and progressive anaemia. Current therapies for CIMF are mostly palliative ...

Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2

... by the results from this ongoing trial that show rapid decrease in spleen size and relief of disease-related symptoms at low doses of XL019. XL019 ... activity observed in most subjects, including: - Reduction in spleen size of 33 to 100% in five of six patients evaluated - ...

Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)

... patients with leukemia cutis had complete or partial clearance of skin lesions. One patient had a 36% reduction in lymph node size, a 28% decrease in spleen size and a significant increase (44%) in hemoglobin. Mild grade 1 or 2 infusion toxicity was observed and there were three dose-limiting toxicities ...

Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders

... low production of platelets in the bone marrow, increased breakdown of platelets in the bloodstream, or increased breakdown of platelets in the spleen or liver, which can be induced by certain anemias, cancers, infections, or medications. Symptoms can include bruising, nose bleeds, bleeding in the ...

Gene Therapy Corrects Sickle Cell Disease in Laboratory Study

... The resulting clogged blood vessels can lead to cognitive dysfunction by causing small strokes in the brain and cause damage to kidneys, liver, spleen and lungs. The only permanent cure for the disease is a bone marrow transplant to give recipients blood-forming cells that will form normal ...

Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody

... of the body. (3) B-cell CLL is characterized by clonal expansion of abnormal B lymphocytes. Patients with CLL also may develop enlargement of the spleen and lymph nodes, and pancytopenia (depletion of red and white blood cells and platelets), ultimately resulting in hemorrhage, infection and death. ...

Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals

... Additionally, the serious side effects previously documented with systemic use of IL-12 were not found in the treated rats. The liver, lung and spleen remained normal throughout the study. The delivery technique through free flaps did not cause liver toxicity, whereas using IL-12 intravenously in ...

Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies

... R788's effect on the immune cascade in an in vivo lupus model, has been published in Arthritis and Rheumatism and is titled - "An Orally Bioavailable spleen Tyrosine Kinase Inhibitor Delays Disease Progression and Prolongs Survival in Murine Lupus," (May 2008, Volume 58, No. 5, p.1433). "These results ...

Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil

... be 6 million people (US, EU and Japan) by 2010. Portal hypertension is the build-up of pressure in the portal vein (the vein carrying blood from the spleen and digestive tract to the liver). A major complication related to portal hypertension is variceal bleeding, where increased pressure causes veins ...

Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH

... kidney in paroxysmal nocturnal haemoglobinuria: MRI findings. Br J Radiol. 2004;77:953-956. (8) Tanaka YO, et al. MR of kidney, liver, and spleen in paroxysmal nocturnal hemoglobinuria. J Comput Assist Tomogr. 1993;17:749-753. (9) Nishimura JI, et al. Clinical course and flow cytometric ...

Surgeons Develop Innovative Life-Saving Treatments to Correct Massive Bleeding in Trauma Patients

... control the bleeding. But what if you have an injury to the abdomen and there is spillage of stool in the abdomen or an injury to the liver or the spleen that continues to spill blood? This study looked at a realistic lifelike trauma scenario," Dr. Alam explained. The findings were presented at the ACS ...

Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease

... in various tissues, including the brain, in mice genetically modified to produce the L444P form of the enzyme. In addition, liver and spleen weights were decreased as were plasma levels of chitin III and IgG, which are biomarkers related to Gaucher disease. The L444P is one ...

Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research

... functionally incompetent long-lived B-lymphocytes (small white blood cells) circulating in the blood, sometimes also causing swelling of lymph nodes, spleen and other organs. The failure of these cancerous B-CLL cells to die is generally thought to be due at least in part to over expression of the Bcl-2 ...

Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA

... In an ongoing phase 1 study, MT103/MEDI-538 has shown potent elimination of tumor target cells in peripheral blood, bone marrow, lymph nodes and spleen of therapy-refractory non-Hodgkins lymphoma patients. About MedImmune, Inc. MedImmune strives to provide better medicines to patients, ...

MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule

... In an ongoing phase 1 study, MT103/MEDI-538 has shown potent elimination of tumor target cells in peripheral blood, bone marrow, lymph nodes and spleen of therapy-refractory non-Hodgkins lymphoma patients. About MedImmune, Inc. MedImmune strives to provide better medicines to patients, ...

Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune

... In an ongoing phase 1 study, MT103/MEDI-538 has shown potent elimination of tumor target cells in peripheral blood, bone marrow, lymph nodes and spleen of therapy- refractory non-Hodgkins lymphoma patients. About Micromet, Inc. (

St. Jude Study Shows Effectiveness of Peramivir in Prevention of Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection

... administration for 7 days. The longer duration of peramivir treatment also prevented viral replication in the tissues of the lungs, brain and spleen of the mice at the 3, 6, and 9 day post-inoculation time points. W. James Alexander, MD, MPH, BioCryst Senior Vice President for Clinical ...

CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago

... surface of colloidal gold nanoparticles, whose design is to: (1) make them invisible to immune detection, thereby avoiding uptake by the liver and spleen and (2) target delivery of TNF directly to tumor sites. At 27 nanometers in size, these nanoparticles are small enough to circulate safely through ...

Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia

... functionally incompetent long-lived B-lymphocytes (small white blood cells) circulating in the blood, sometimes also causing swelling of lymph nodes, spleen and other organs. The failure of these cancerous B-CLL cells to die is generally thought to be due at least in part to over expression of the Bcl-2 ...